16 February 2005 10:17 [Source: ICIS news]
LONDON (CNI)--Dutch biotechnology company Crucell and contract manufacturer DSM Biologics said Wednesday that they have signed a research licence agreement with Swiss pharmaceuticals group Roche for the use of Crucell's PER.C6 cell line.
In a statement, Crucell said that Roche will use the technology for production of monoclonal antibody products and a “specific undisclosed protein” and had selected the cell line as it retains features which it says are “capable of delivering the appropriate product quality”.
Crucell will work with Roche in creating a production clone for the specific protein. Roche will pay research licence and annual maintenance fees and provide research funding. Further financial details were not disclosed.
In 2004, Crucell signed PER.C6 licence agreements with UK pharmaceutical company ML Laboratories for use in the development and manufacture of gene therapy products and with Franco-German life sciences group Aventis for the development of influenza vaccines.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections